Regenexx   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Broomfield CO United States (2005)

Organization Overview

First Clinical Trial
2012
NCT02021097
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Centeno-Schultz Clinic | Regenerative Sciences, LLC | Regenex Pharmaceutical, China | Regenexx and Centeno-Schultz Clinic | Regenexx, LLC | Regenexx, LLC and Centeno-Schultz Clinic

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis, Knee (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 10